title: Effect of flurenizide on adaptive reactions in patients with chronic obstructive pulmonary disease.
abstract: A total of 75 patients with chronic obstructive pulmonary disease (COPD) was investigated, 50 of which received Flurenizide in addition to traditional therapy. The remaining 25 received traditional therapy only and constituted the control group. Clinical improvement was observed in both groups, but this was attained in different ways. This depended on the type of the adaptive reactions at the beginning of exacerbation and the transition from one reaction to the other. In the basic group that received Flurenizide, clinical improvement was attained by a transition from physical conditions of defective adaptation (DA) or reaction of orientation (RO) into positive reactions of slight (RSA) or elevated (REA) activation in 72% of patients. Negative transition was not observed, and 14% of the patients remained in the DA condition. In the control group, a transition from DA into RO was observed in 27% of the patients, while 73% remained in DA without any positive adaptive reactions being definable. A significant improvement in the parameters of immunological and lung function tests was observed only in the group of patients who received Flurenizide. The highest levels of the above-mentioned parameters were observed in patients whose adaptive reactions had transited into the RSA or REA condition. We suggest that the reason for this positive dynamics was induced by the immunostimulating effect of Flurenizide.
authors.affiliation: Medical Institute, Lviv, Ukraine.
authors.forename: M V
authors.initials: MV
authors.lastname: Panchyshyna
authors.forename: Y A
authors.initials: YA
authors.lastname: al-Qdemat
authors.forename: J M
authors.initials: JM
authors.lastname: Panchyshyn
authors.forename: L I
authors.initials: LI
authors.lastname: Petruh
authors.forename: T G
authors.initials: TG
authors.lastname: Kazmirchuk
mesh_terms: D000222:Adaptation, Physiological; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000917:Antibody Formation; D005260:Female; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000091402:Prohibitins
chemical_list: D000276:Adjuvants, Immunologic; D006571:Heterocyclic Compounds; C000717331:PHB2 protein, human; D000091402:Prohibitins; C065925:flurenizid